Investors have been buying up struggling companies in the hope of a relief rally. But Matthew Brooks says they’re too early ...

Police have started an inquiry after a message reading “I Love Pakistan” was found written inside a vessel that arrived at Cochin Shipyard here for maintenance, officials said on Thursday. Kochi City ...

"At the end of this exhausting day, even pausing to catch your breath is a kind of living ..." (from "The Miracle That Is You ...

The Australian sharemarket ended the day in positive territory as gold rebounded after hitting an eight-month low, but local ...

Australian shares are set for a weaker start, with ASX futures pointing to a decline after US markets fell sharply overnight amid renewed geopolitical tensions in the Middle East and growing ...

In 2015, Ethereum co-founder Charles Hoskinson left the project he helped build and started over. Apparently, his vision was a blockchain built differently. That project became Cardano. If you ...

It still needs to rebuild trust, but lower expectations and several recovery levers make the shares worth considering. The ...

Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL Ltd (ASX: CSL) has long been lauded as a shining example of homegrown Australian ingenuity succeeding on a world stage, and as such, has been a mainstay in many investors' portfolios. The ...

Travere Therapeutics and partner CSL Vifor could be weeks away from EU approval of sparsentan for IgA nephropathy, after getting a positive opinion on the drug from the EMA’s human medicines committee ...